Financial ChallengesManagement is making early progress extending the cash runway with ~$850MM currently in hand, but there is potential for ~$400MM in annual burn, which is well above management targets.
Regulatory And Reimbursement RisksThere are inherent risks associated with broadly commercializing novel technologies such as MCEDs, including an uncertain regulatory and reimbursement pathway.
Revenue DeclineDevelopment services revenue declined by 13% year-over-year, indicating a slowdown in this segment of Grail Inc's business.